Abbott Laboratories
ABT (NYSE)
Abbott Laboratories stands out as a U.S. healthcare company known for its reliable dividend growth and diverse portfolio spanning diagnostics, devices, and nutrition. Despite a challenging year with a -14.19% return, it offers an attractive dividend yield of 2.78%, appealing to income-focused investors. Analysts remain optimistic, maintaining a median 12-month price target of $121, with recommendations from firms like TD Cowen and Citigroup reflecting a Buy rating, highlighting its strong market position.
Pros:
- Consistent dividend growth
- Broad exposure across healthcare sectors
Cons:
- Negative returns in recent years
- Market competition in healthcare
Abbott Laboratories (ABT) may be a suitable investment for income-focused investors seeking reliable dividend growth in the healthcare sector, despite recent performance challenges reflected in its -14.19% one-year return. With a median price target indicating potential upside and strong analyst support, it offers a balanced opportunity for those willing to navigate market volatility while prioritizing dividend income.